Elan Prialt On Track For Q4 Approval; NDA To Seek Acute & Chronic Use
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Elan plans to focus the launch of its non-opioid analgesic Prialt on cancer, AIDS and neuropathic pain before expanding to broader populations.
You may also be interested in...
Elan Prialt amendment
Elan expects to launch its non-opioid analgesic Prialt (ziconotide) in early 2005 following a June 28 amendment that is expected to receive a six-month review. The submission includes a 21-day trial (conducted in response to a July 2001 "approvable" letter) showing statistically significant results "at lower doses and following a slower titration schedule" than previously studied, Elan says. Prior studies focused on cancer, AIDS and neuropathic pain (1Pharmaceutical Approvals Monthly Jan. 1, 2004, p. 20). Elan is seeking approval for severe chronic pain...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product